Girdin (GIV) Expression as a Prognostic Marker of Recurrence in Mismatch Repair-Proficient Stage II Colon Cancer


Por: Ghosh, P, Tie, J, Muranyi, A, Singh, S, Brunhoeber, P, Leith, K, Bowermaster, R, Liao, Z, Zhu, Y, LaFleur, B, Tran, B, Desai, J, Jones, I, Croxford, M, Jover R, Goel, A, Waring, P, Hu, S, Teichgraber, V, Rohr, U, Ridder, R, Shanmugam, K and Gibbs, P

Publicada: 15 jul 2016
Resumen:
Purpose: Prognostic markers that identify patients with stage II colon cancers who are at the risk of recurrence are essential to personalize therapy. We evaluated the potential of GIV/Girdin as a predictor of recurrence risk in such patients. Experimental Design: Expression of full-length GIV was evaluated by IHC using a newly developed mAb together with a mismatch repair (MMR)-specific antibody panel in three stage II colon cancer patient cohorts, that is, a training (n = 192), test (n = 317), and validation (n = 181) cohort, with clinical follow-up data. Recurrence risk stratification models were established in the training cohort of T3, proficient MMR (pMMR) patients without chemotherapy and subsequently validated. Results: For T3p MMR tumors, GIV expression and the presence of lymphovascular invasion (LVI) were the only factors predicting recurrence in both training (GIV: HR, 2.78, P = 0.013; LVI: HR, 2.54, P = 0.025) and combined test and validation (pooled) cohorts (GIV: HR, 1.85, P = 0.019; LVI: HR, 2.52, P = 0.0004). A risk model based on GIV expression and LVI status classified patients into high-or low-risk groups; 3-year recurrence-free survival was significantly lower in the high-risk versus low-risk group across all cohorts [Training: 52.3% vs. 84.8%; HR, 3.74, 95% confidence interval (CI), 1.50-9.32; Test: 85.9% vs. 97.9%, HR, 7.83, 95% CI, 1.03-59.54; validation: 59.4% vs. 84.4%, HR, 3.71, 95% CI, 1.24-11.12]. Conclusions: GIV expression status predicts recurrence risk in patients with T3 pMMR stage II colon cancer. A risk model combining GIV expression and LVI status information further enhances prediction of recurrence. Further validation studies are warranted before GIV status can be routinely included in patient management algorithms. = 2016 AACR.

Filiaciones:
Ghosh, P:
 Univ Calif San Diego, Dept Med, San Diego, CA 92103 USA

 Univ Calif San Diego, Dept Cell & Mol Biol, San Diego, CA 92103 USA

Tie, J:
 Walter & Eliza Hall Inst Med Res, Melbourne, Vic, Australia

 Royal Melbourne Hosp, Grattan St, Melbourne, Vic 3050, Australia

 Western Hosp, Melbourne, Vic, Australia

Muranyi, A:
 Ventana Med Syst Inc, 1910 E Innovat Pk Dr, Tucson, AZ 85755 USA

Singh, S:
 Ventana Med Syst Inc, 1910 E Innovat Pk Dr, Tucson, AZ 85755 USA

Brunhoeber, P:
 Ventana Med Syst Inc, 1910 E Innovat Pk Dr, Tucson, AZ 85755 USA

Leith, K:
 Ventana Med Syst Inc, 1910 E Innovat Pk Dr, Tucson, AZ 85755 USA

Bowermaster, R:
 Ventana Med Syst Inc, 1910 E Innovat Pk Dr, Tucson, AZ 85755 USA

Liao, Z:
 Spring Biosci, Pleasanton, CA USA

Zhu, Y:
 Spring Biosci, Pleasanton, CA USA

LaFleur, B:
 Ventana Med Syst Inc, 1910 E Innovat Pk Dr, Tucson, AZ 85755 USA

Tran, B:
 Walter & Eliza Hall Inst Med Res, Melbourne, Vic, Australia

 Royal Melbourne Hosp, Grattan St, Melbourne, Vic 3050, Australia

 Western Hosp, Melbourne, Vic, Australia

Desai, J:
 Walter & Eliza Hall Inst Med Res, Melbourne, Vic, Australia

 Royal Melbourne Hosp, Grattan St, Melbourne, Vic 3050, Australia

Jones, I:
 Royal Melbourne Hosp, Grattan St, Melbourne, Vic 3050, Australia

Croxford, M:
 Western Hosp, Melbourne, Vic, Australia

Jover R:
 Hosp Gen Univ Alicante, Dept Gastroenterol, Alicante, Spain

Goel, A:
 Baylor Univ, Med Ctr, Baylor Res Inst, Houston, TX 77030 USA

 Baylor Univ, Med Ctr, Charles A Sammons Canc Ctr, Houston, TX 77030 USA

Waring, P:
 Univ Melbourne, Dept Pathol, Melbourne, Vic 3010, Australia

Hu, S:
 F Hoffmann La Roche & Cie AG, Basel, Switzerland

Teichgraber, V:
 F Hoffmann La Roche & Cie AG, Basel, Switzerland

Rohr, U:
 F Hoffmann La Roche & Cie AG, Basel, Switzerland

Ridder, R:
 Ventana Med Syst Inc, 1910 E Innovat Pk Dr, Tucson, AZ 85755 USA

Shanmugam, K:
 Ventana Med Syst Inc, 1910 E Innovat Pk Dr, Tucson, AZ 85755 USA

Gibbs, P:
 Walter & Eliza Hall Inst Med Res, Melbourne, Vic, Australia

 Royal Melbourne Hosp, Grattan St, Melbourne, Vic 3050, Australia

 Western Hosp, Melbourne, Vic, Australia
ISSN: 10780432





CLINICAL CANCER RESEARCH
Editorial
AMER ASSOC CANCER RESEARCH, 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA, Estados Unidos America
Tipo de documento: Article
Volumen: 22 Número: 14
Páginas: 3488-3498
WOS Id: 000381113000010
ID de PubMed: 27029492

MÉTRICAS